RE: oh dear8 Feb 2021 18:35
As usual Gam throws in a hand grenade and then refuses to debate the facts. It amazes me that in recent days I've fronted up to some real risks facing this project but the bashers want to de-ramp in a parallel universe, I can only conclude that they don't understand the actual risks and prefer to populate this fantasy land of evil Exec's conjuring up devilish schemes to kick out small investors, total transparency, put to bed, no issue. Where there isn't transparency is the critical subject of impurities, there is no way in the world that AH or Conrad are going into negotiations saying these are the delet's we don't have but we can't discuss the ones that have been detected, which is the story being sold to PI's. Now as I said yesterday the risk / reward is still very much in our favour particularly from these levels, but the issue of the impact of negative by-products has been put as early as a 2018 presentation, by me privately and I would assume many others, myself at the AGM and more recently by a contributor to the analysts webinar, to my dismay it has been dodged every time. Raising this on here might appear odd from someone who expects to make good return from EUZ but frankly I'm PO'd with this being batted away time and time again, they need to grasp the nettle and bring us up to speed. When DB agreed to fund us again at 12.75p I am certain that their analysts would have been made fully aware of our impurities and they will have calculated the impact on our economics, nobody increases their position by £400,000 without knowing all the facts. That gives me confidence but it also irritates me they won't tell us publicly which deleterious elements are lurking in our concentrate, there is even a case that this constitutes withholding price sensitive information.